ONCAlert | 2018 Gastrointestinal Cancers Symposium

Brain Cancer MORE >>

Treatment with lomustine plus bevacizumab provided a slightly improved progression-free survival, but did not demonstrate an overall survival advantage over treatment with lomustine alone in patients with progressive glioblastoma, according to results of a randomized phase III trial published in the New England Journal of Medicine.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.